Insider Selling: NantKwest, Inc. (NASDAQ:NK) CFO Sells 16,364 Shares of Stock
NantKwest, Inc. (NASDAQ:NK) CFO Sonja Nelson sold 16,364 shares of the business’s stock in a transaction that occurred on Tuesday, January 12th. The stock was sold at an average price of $15.00, for a total transaction of $245,460.00. Following the completion of the sale, the chief financial officer now owns 31,774 shares in the company, valued at $476,610. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
Sonja Nelson also recently made the following trade(s):
- On Monday, January 4th, Sonja Nelson sold 39,271 shares of NantKwest stock. The stock was sold at an average price of $13.62, for a total transaction of $534,871.02.
NantKwest stock opened at $14.78 on Thursday. The firm has a market cap of $1.61 billion, a PE ratio of -20.82 and a beta of 2.52. The firm’s 50 day moving average price is $12.33 and its two-hundred day moving average price is $10.05. NantKwest, Inc. has a twelve month low of $2.52 and a twelve month high of $19.37.
Institutional investors have recently added to or reduced their stakes in the business. Bank of Montreal Can acquired a new position in NantKwest in the 2nd quarter valued at approximately $32,000. FNY Investment Advisers LLC acquired a new position in NantKwest in the 3rd quarter valued at approximately $41,000. Point72 Hong Kong Ltd acquired a new position in NantKwest in the 3rd quarter valued at approximately $48,000. BNP Paribas Arbitrage SA increased its stake in NantKwest by 522.8% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 7,231 shares of the biotechnology company’s stock valued at $50,000 after buying an additional 6,070 shares during the period. Finally, Fifth Third Bancorp bought a new stake in NantKwest in the third quarter worth approximately $51,000. Hedge funds and other institutional investors own 9.22% of the company’s stock.
NantKwest, Inc, a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and Nant cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells.
See Also: Return On Assets
Receive News & Ratings for NantKwest Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantKwest and related companies with MarketBeat.com's FREE daily email newsletter.